

24 November 2015 EMA/HMPC/16635/2009 Corr. <sup>1</sup> Committee on Herbal Medicinal Products (HMPC)

# Community herbal monograph on *Vitis vinifera* L., folium Final

Discussion in Working Party on Community monographs and Community	March 2009
list (MLWP)	July 2009
	September 2009
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	12 November 2009
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu	15 April 2010
Rediscussion in Working Party on Community monographs and	May 2010
Community list (MLWP)	July 2010
Adoption by Committee on Herbal Medicinal Products (HMPC)	15 July 2010

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; well-
	established medicinal use; traditional use; Vitis vinifera L.; Vitis viniferae
	folium; grapevine leaf

BG (bălgarski): лоза, лист	LT (lietuvių kalba): Tikrųjų vynmedžių lapai
CS (čeština): Červený list vinné révy	LV (latviešu valoda): Īstā vīnkoka lapas
DA (dansk): Vinblad	MT (malti): Werqa tad-dielja
DE (Deutsch): Rote Weinrebenblätter	NL (nederlands): Wijnstokblad
EL (elliniká): Φὐλλο Αμπέλου	PL (polski): Liść winorośli właściwej
EN (English): Grapevine leaf	PT (português): Folha de videira
ES (espanol): Vid, hoja de	RO (română): Frunze de viţă-de-vie
ET (eesti keel): Viinapuu lehed	SK (slovenčina): List viniča
FI (suomi): Aitoviiniköynnös, lehti	SL (slovenščina): List vinske trte
FR (français): Feuille de vigne rouge	SV (svenska): Blad från vinranka
HU (magyar): Bortermő szőlő levél	IS (íslenska): Vínviðarlauf
IT (italiano): Vite, foglia	NO (norsk): Rød vinranke, blad





<sup>&</sup>lt;sup>1</sup> Correction of ATC code

### Community herbal monograph on Vitis vinifera L., folium

# 1. Name of the medicinal product

To be specified for the individual finished product.

# 2. Qualitative and quantitative composition 2,3

Well-established use	Traditional use
With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Vitis vinifera L., folium	Vitis vinifera L., folium
(grapevine leaf) <sup>4</sup>	(grapevine leaf) <sup>5</sup>
i) Herbal substance	i) Herbal substance
Not applicable.	Not applicable.
ii) Herbal preparation	ii) Herbal preparation
Dry extract (DER 4-6:1); extraction solvent	a) Comminuted herbal substance
water	b) Powdered herbal substance
	c) Soft extract (DER 2.5-4:1); extraction solvent water

### 3. Pharmaceutical form

Well-established use	Traditional use
Herbal preparation in solid dosage forms for oral use.	Comminuted herbal substance as herbal tea for oral use.
	Herbal preparation in solid dosage forms for oral use.
	Herbal preparation in semi-solid dosage forms for cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term

<sup>2</sup> The material complies with the Ph. Eur. monograph (ref.: 01/2008:1374).

<sup>3</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>4</sup> and 4 The material complies with the monograph of the Pharmacopée Française X., 1996

# 4. Clinical particulars

# 4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product for treatment of chronic venous insufficiency, which is characterised by swollen legs, varicose veins, a feeling of heaviness, pain, tiredness, itching, tension and cramps in the calves.	Indication 1)  Traditional herbal medicinal product to relieve symptoms of discomfort and heaviness of legs related to minor venous circulatory disturbances.  Indication 2)  Traditional herbal medicinal product for symptomatic relief of itching and burning associated with haemorrhoids.  Indication 3)  Traditional herbal medicinal product for symptomatic treatment of cutaneous capillary fragility.  The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

# 4.2. Posology and method of administration

Well-established use	Traditional use
Posology	Posology
Adults and elderly	Indication 1)
Dry extract (DER 4-6:1; water)	Adults and elderly
Single dose: 360-720 mg Daily dose: 360-720 mg	Oral use
Use in children and adolescents	a) Comminuted herbal substance as herbal tea 5-10 g/250 ml, 2 times daily.
The use in children and adolescents under  18 years of age is not recommended (see section  4.4 'Special warnings and precautions for use')	b) Powdered herbal substance 270-350 mg, 3-5 times daily.
Duration of use	Cutaneous use
The recommended duration of use is 12 weeks.  Two to three weeks of treatment may be required	c) Soft extract (DER 2.5-4:1; water) in a cream base (10 g contain 282 mg soft extract).
before beneficial effects are observed.	Apply a thin layer on the affected area 1-3 times
Long term use is possible in consultation with a	daily.
doctor.	

Method of administration	Indication 2) and 3)
Oral use.	Adults and elderly
	Oral use
	a) Comminuted herbal substance as herbal tea 5-10 g/250 ml, 2 times daily.
	b) Powdered herbal substance 270-350 mg, 3-5 times daily.
	Duration of use
	Indication 1)
	The recommended duration of use is 4 weeks.  If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.  Indications 2) and 3)
	If the symptoms persist for more than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Method of administration
	Oral use.
	Cutaneous use.

### 4.3. Contraindications

Well-established use	Traditional use
Hypersensitivity to the active substance.	Hypersensitivity to the active substance.

### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
If there is inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency, a doctor should be consulted.	Indication 1)  If there is inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency, a doctor
In the event of inadequate or unsatisfactory	should be consulted.

symptomatic response within 2 weeks, a doctor should be consulted as oedema may have alternative causes.

In the absence of sufficient safety data, the use in children and adolescents below 18 years of age is not recommended.

The product should not be used on broken skin, around the eyes or on mucous membranes. Oral use: In the event of inadequate or unsatisfactory symptomatic response within 2 weeks, a doctor should be consulted as oedema may have alternative causes.

#### Indication 2)

If rectal bleeding occurs during the treatment of haemorrhoids a doctor or a qualified health care practitioner should be consulted.

In the event of inadequate or unsatisfactory symptomatic response within 1 week, a doctor should be consulted.

### Indication 3)

In the event of inadequate or unsatisfactory symptomatic response within 1 week, a doctor should be consulted as oedema may have alternative causes.

In the absence of sufficient safety data, the use in children and adolescents below 18 years of age is not recommended.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
Not known.	Not known.

### 4.6. Pregnancy and lactation

Well-established use	Traditional use
Safety during pregnancy and lactation has not	Safety during pregnancy and lactation has not
been established. In the absence of sufficient	been established. In the absence of sufficient
data, the use during pregnancy and lactation is	data, the use during pregnancy and lactation is
not recommended.	not recommended.

### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
No studies on the effect on the ability to drive and use machines have been performed.	No studies on the effect on the ability to drive and use machines have been performed.

### 4.8. Undesirable effects

Well-established use	Traditional use
Hypersensitivity reactions of the skin (itching and erythema, urticaria) have been reported. The frequency is not known.  Nausea, gastrointestinal complaints and headache may occur. The frequency is not known.  If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.	Indication 1), 2) and 3)  Contact allergy and/or hypersensitivity reactions of the skin (itching and erythema, urticaria) have been reported. The frequency is not known.  Oral use  Nausea, gastrointestinal complaints and headache may occur. The frequency is not known.  If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

### 4.9. Overdose

Well-established use	Traditional use
No cases of overdose have been reported.	No case of overdose has been reported.

# 5. Pharmacological properties

### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
Pharmacotherapeutic group:	Not required as per Article 16c(1)(a)(iii) of
Other capillary stabilizing agents	Directive 2001/83/EC as amended.
ATC code:	
CO5CX	
The efficacy of orally administered dry extract of red vine leaves (4-6:1) in reducing oedema has been studied in patients suffering from chronic venous insufficiency (CVI, grade I or II).  Grapevine leaf extract improves the microvascular blood flow in CVI patients.	

### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
Not known.	Not required as per Article 16c(1)(a)(iii) of
	Directive 2001/83/EC as amended.

### 5.3. Preclinical safety data

Well-established use	Traditional use
No signs of acute toxicity in rats or mice after oral administration of 10,000 mg/kg body weight.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless
No sub-acute toxicity in rats, in doses up to	necessary for the safe use of the product.
250 mg/kg body weight daily for 90 days.  In the micronucleus test, the gene mutation test in V79 cells of Chinese hamsters and the Ames	Tests on genotoxicity and reproductive toxicity do not give any reason for concern for the cutaneous use of the soft extract (2.5-4:1; water).
Salmonella/microsome plate incorporation test the extract of grapevine leaf proved not to be mutagenic.	Tests on genotoxicity, carcinogenicity and reproductive toxicity have not been performed for comminuted and powdered preparations.
The teratogenicity study in rabbits (treatment from 6 <sup>th</sup> -18 <sup>th</sup> day of pregnancy) did not reveal any toxic effects in doses up to 3.000 mg/kg body weight.	
Tests on genotoxicity and reproductive toxicity do not give any reason for concern.	
Tests on carcinogenicity have not been performed.	

# 6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable.	Not applicable.

# 7. Date of compilation/last revision

15 July 2010